The presentation of positive clinical data at a major conference like ASH can enhance investor confidence in Keros Therapeutics' pipeline, potentially leading to a short-term increase in stock price. The focus on myelodysplastic syndromes and myelofibrosis, areas with significant unmet medical needs, further underscores the potential impact.